Catalent (NYSE:CTLT) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a research note issued to investors on Thursday.

A number of other equities analysts have also recently weighed in on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Finally, Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Nine analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $59.83.

Catalent Trading Up 0.7 %

Shares of Catalent stock traded up $0.40 during trading hours on Thursday, reaching $59.31. The stock had a trading volume of 441,767 shares, compared to its average volume of 2,030,142. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent has a 1 year low of $36.74 and a 1 year high of $61.20. The firm has a 50 day simple moving average of $59.89 and a two-hundred day simple moving average of $58.16.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, analysts expect that Catalent will post 0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 in the last three months. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Melqart Asset Management UK Ltd increased its holdings in shares of Catalent by 159.0% during the 3rd quarter. Melqart Asset Management UK Ltd now owns 1,030,240 shares of the company’s stock worth $62,402,000 after acquiring an additional 632,515 shares during the last quarter. Investment Management Corp of Ontario grew its holdings in Catalent by 49.7% in the 3rd quarter. Investment Management Corp of Ontario now owns 6,022 shares of the company’s stock valued at $365,000 after buying an additional 2,000 shares in the last quarter. Harvest Management LLC bought a new position in Catalent during the 3rd quarter worth $7,589,000. HGC Investment Management Inc. acquired a new stake in shares of Catalent during the third quarter worth $4,219,000. Finally, Athos Capital Ltd bought a new stake in shares of Catalent in the third quarter valued at about $6,009,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.